EGFR and lung cancer: We reasoned therefore that if the Hippo pathway was important in mediating drug resistance in EGFR mutant lung cancer, this might be (a) through non-genetic mechanisms and (b) be involved at a much earlier stage of treatment response, i.e. acutely in maintaining the survival of drug-tolerant persister cells.